Oxytocin versus a combination of tranexamic acid and ethamsylate in reducing intraoperative bleeding during abdominal myomectomy: a randomized clinical trial.

What Was Tested

Researchers studied Oxytocin in this randomized controlled trial publication.

Myomectomy is the preferred surgical approach to manage uterine fibroids.

However, uterine fibroids are highly vascular tumors and, consequently, extremely susceptible to problems from myomectomy-related hemorrhage.

Why It Was Studied

The study was registered on Pan African Clinical Trials Registry with the following number: PACTR202008739887429 and was approved on 24/08/2020.

Who Took Part

PubMed tags the participants as women only.

How the Study Was Run

The researchers set it up as a randomized, double-blind and multicenter study.

Because people in this Oxytocin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Oxytocin.

Running at several centres spread the Oxytocin study over different clinics and patient groups.

This randomized, double-blinded multicenter study was performed between 20th August 2020 and 20th October 2020 at El-Galaa Teaching Hospital, El Hussein University Hospital, Al-Azhar University Hospitals of Assiut, and Al-Azhar University Hospitals of Damietta.

What Was Measured

Topics PubMed links to this paper include Ethamsylate, Tranexamic Acid, Uterine Myomectomy, Oxytocin, Blood Loss, Surgical, Saline Solution and Leiomyoma.

Author keywords: Abdominal myomectomy.

What This Means in Plain Language

The paper is a randomized, double-blind and multicenter study of Oxytocin.

Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2023 (BMC women's health), a journal based in England.

More context: the Oxytocin compound page, all human trials.